Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD gives update on Achieve trial

MSD gives update on Achieve trial

2nd April 2008

Following a recommendation from the steering committee, Merck, Sharp and Dohme (MSD) has given an update on the progress of the Achieve trial of Cordaptive (niacin/laropiprant).

The firm notes that further patient enrolment in the programme has been put on hold, which will facilitate the evaluation of the current study in the context of recently-released data from intima-media thickness (IMT) studies by the steering committee.

MSD confirms that ongoing clinical studies of Cordaptive, including those known under the HPS2-Thrive banner, remain unchanged.

The company said that it has begun to notify the relevant regulatory agencies and study investigators of this decision.

John Kastelein, chair of the steering committee, said: “Since Achieve was originally designed, the understanding of carotid IMT studies has evolved leading the committee to decide to take this action.”

Christie Ballantyne, chief of the atherosclerosis and vascular medicine section at the Baylor College of Medicine and the Methodist DeBakey Heart Centre said that patients already enrolled in Achieve will be followed according to existing protocol.

In September 2007, MSD announced positive phase III clinical trial results for Cordaptive, with the drug reducing the level of triglycerides and LDL-cholesterol while increasing HDL-cholesterol compared to placebo.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.